Lifecome Biochemistry Co.,Ltd.

Shenzhen Stock Exchange 002868.SZ

Lifecome Biochemistry Co.,Ltd. Current Liabilities for the year ending December 31, 2023: USD 131.03 M

Lifecome Biochemistry Co.,Ltd. Current Liabilities is USD 131.03 M for the year ending December 31, 2023, a 86.39% change year over year. Current liabilities are obligations that are expected to be settled within one year, including accounts payable, short-term debt, and other current liabilities.

Lifecome Biochemistry Co.,Ltd. Current Liabilities for the year ending December 31, 2022 was USD 70.30 M, a 14.44% change year over year.
Lifecome Biochemistry Co.,Ltd. Current Liabilities for the year ending December 31, 2021 was USD 61.43 M, a 216.19% change year over year.
Lifecome Biochemistry Co.,Ltd. Current Liabilities for the year ending December 31, 2020 was USD 19.43 M, a -1.70% change year over year.
Lifecome Biochemistry Co.,Ltd. Current Liabilities for the year ending December 31, 2019 was USD 19.76 M, a 162.66% change year over year.

Key data

Date	Current Liabilities	Total Non-Current Liabilities	Shareholders' Equity	Long-Term Debt

Shenzhen Stock Exchange: 002868.SZ

Lifecome Biochemistry Co.,Ltd.

CEO	Mr. Zhongshou Bao
IPO Date	May 3, 2017
Location	China
Headquarters	No. 19,Nanpu Ecological Industrial Park
Employees	992
Sector	Consumers Staples
Industries Personal Care Biotechnology Cleaning Supplies Cosmetics Fertilizers Pet Food Pharmaceuticals Plastics

Description

Lifecome Biochemistry Co.,Ltd. operates as a biopharmaceutical company in China. It primarily offers bacitracin zinc products, colistin sulfate products, probiotics products, bacitracin methylene disalicylate products, biological preservatives, natamycin products, etc. The company was founded in 2003 and is based in Pucheng, China.

Key trends

Past 5 years